Research Papers:

Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth

Che-Hsin Lee, Tomoyuki Nishikawa and Yasufumi Kaneda _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:35048-35060. https://doi.org/10.18632/oncotarget.17037

Metrics: PDF 1441 views  |   HTML 2202 views  |   ?  


Che-Hsin Lee1,2, Tomoyuki Nishikawa3, Yasufumi Kaneda3

1Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan

2Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan

3Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka, Japan

Correspondence to:

Che-Hsin Lee, email: [email protected]

Yasufumi Kaneda, email: [email protected]

Keywords: Salmonella, targeted therapy, polymer, hemagglutinating virus of Japan-envelope

Received: December 08, 2016     Accepted: March 30, 2017     Published: April 11, 2017


Salmonella can target to tumor microenvironments after systemic treatment. The hemagglutinating virus of Japan-envelope (HVJ-E) induced apoptosis in tumor cells without toxicity in normal cells. Current HVJ-E therapeutic strategies, aimed at using HVJ-E for intratumor treatment, have shown great promise in animal models but have achieved only limited systemic treatment. The purpose of this study was to investigate the modulation of the anti-tumor efficiency of HVJ-E by coating the particles with poly (allylamine hydrochloride) (PAH), designated as P-HVJ-E. Treatment with P-HVJ-E resulted in decreased hemagglutinating activity and maintained tumor cell-selective apoptosis and anti-tumor immunity. The use of Salmonella as a coating for P-HVJ-E (PHS) enhanced the antitumor activity and maintained the tumor-targeting activity. Treatment with PHS resulted in delayed tumor growth in tumor-bearing mice. Furthermore, a Western blot assay of the tumors revealed that HVJ-E targeted to the tumor after systemic treatment with PHS. These results indicate that Salmonella coating viral particles may provide a new approach for tumor therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17037